AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2014
Oct 1, 2014
31523_dirs_2014-10-01_855dc856-591a-40d9-a5d8-e4d02bb2f44f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2014-09-29
Reporting Person: Peist Kenneth (VP, Legal & IP)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-09-29 | Common stock | P | 28208 | $6.0906 | Acquired | 78208 | Direct |
| 2014-09-29 | Common stock | S | 28208 | $6.0906 | Disposed | 50000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-09-29 | Stock Options (right to buy) | $2.52 | M | 10208 | Disposed | 2023-06-18 | Common Stock (10208) | Direct |
| 2014-09-29 | Stock Options (right to buy) | $3.32 | M | 10000 | Disposed | 2020-03-16 | Common Stock (10000) | Direct |
| 2014-09-29 | Stock Options (right to buy) | $2.81 | M | 8000 | Disposed | 2020-06-15 | Common Stock (8000) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2014.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $5.94 to $6.25. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $5.94 to $6.25. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.